Biblio
2024
Nasri M, Ritter M, Mir P, Dannenmann B, Kaufmann MM, Arreba-Tutusaus P, Xu Y, Borbaran-Bravo N, Klimiankou M, Lengerke C, et al. CRISPR/Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia. Mol Ther. 2024.
2023
Zeidler A, Borbaran-Bravo N, Dannenmann B, Ritter M, Nasri M, Klimiankou M, Kandabarau S, Zahabi A, König J, Zeidler C, et al. Differential transcriptional control of hematopoiesis in congenital and cycling neutropenia patients harboring mutations. Haematologica. 2023.
Pogozhykh D, Karapinar DYilmaz, Klimiankou M, Gerschmann N, Ebetsberger-Dachs G, Palmblad J, Carlsson G, Masmas T, Kinsey S, Bartels M, et al. HAX1-related congenital neutropenia: Long-term observation in paediatric and adult patients enrolled in the European branch of the Severe Chronic Neutropenia International Registry (SCNIR). Br J Haematol. 2023.
2021
Dannenmann B, Klimiankou M, Oswald B, Solovyeva A, Mardan J, Nasri M, Ritter M, Zahabi A, Arreba-Tutusaus P, Mir P, et al. iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia. Cell Stem Cell. 2021.
2019
Dannenmann B, Zahabi A, Mir P, Oswald B, Bernhard R, Klimiankou M, Morishima T, Zeidler C, Kanz L, Lachmann N, et al. Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34 cells preceding leukemic transformation. Exp Hematol. 2019.
2014
Makaryan V, Zeidler C, Bolyard AAnna, Skokowa J, Rodger E, Kelley ML, Boxer LA, Bonilla MAnn, Newburger PE, Shimamura A, et al. The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Curr Opin Hematol. 2014.
]